BTX - Mergers and acquisitions

NEW YORK, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that gene editing/cell and cytokine therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended June 30, 2021. Financial and corporate highlights for the quarter ended June 30, 2021 and subsequently include the following: Completed the acquisition of Novellus Therapeutics Limited ("Novellus") in July 2021. Novellus is developing next-generation engineered mesenchymal stem cell ("MSC") therapies using patented mRNA-based cell reprog

Brooklyn ImmunoTherapeutics LLC (NYSE:BTX) ("Brooklyn") today announced it has acquired an exclusive license for mRNA gene editing and cell therapies technology of Factor Bioscience Limited and Novellus Therapeutics Limited pursuant to an exercise of a previously announced option. The license includes use of an extensively patented process to develop gene editing compounds using mRNA, which preclinical data suggest demonstrate a high degree of efficiency, as well as being non-immunogenic and non-mutagenic. The licensed platform includes mRNA cell reprogramming, which is considered to be the highest efficiency and footprint-free technology that can be applied to both allogeneic and autolog